Semax Dosage Protocol Guide: Intranasal Research Protocols, Reconstitution & BDNF Mechanisms (2026)

> Research Use Only (RUO): Semax is a synthetic research peptide not approved by the FDA for human use in the United States or EU. All dosage figures, protocols, and study citations on this page are drawn from published preclinical and investigational research. This content is intended solely for qualified researchers. Nothing here constitutes medical advice, diagnosis, or treatment recommendations.

---

Semax occupies a distinctive position in peptide research: a compound with over 30 years of Russian clinical investigation, a well-characterized primary mechanism (BDNF/NGF upregulation), and a delivery method -- intranasal administration -- that is both practical and backed by the strongest evidence base in its class. This guide covers the published dosage ranges, reconstitution procedure, concentration math, and storage requirements for researchers working with Semax under appropriate institutional oversight.

For a foundational overview of Semax's pharmacology, see the Semax Research Profile on this site.

---

What Is Semax? The ACTH(4-10) Heptapeptide

Semax was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Its amino acid sequence is Met-Glu-His-Phe-Pro-Gly-Pro -- a modification of the ACTH(4-10) fragment with a Pro-Gly-Pro tail engineered to extend metabolic stability and enhance CNS penetration.

The original ACTH(4-7) fragment (Met-Glu-His-Phe) is responsible for most of the peptide's CNS-active properties. The Pro-Gly-Pro extension was added to protect against rapid enzymatic degradation in plasma and nasal mucosa, giving Semax a research-practical shelf life after reconstitution that the raw fragment lacks.

Critically, the modification removes ACTH's adrenocortical signaling activity. Semax does not stimulate cortisol release or HPA-axis activation at research doses -- it targets CNS neurotrophic pathways specifically.

---

Primary Mechanism: BDNF and NGF Upregulation

The dominant mechanism studied in Semax research is rapid, measurable upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) mRNA in the hippocampus, prefrontal cortex, and basal forebrain.

Key research findings:

• •Dolotov et al. (2006): A single intranasal Semax administration increased BDNF protein and TrkB receptor signaling in the rat hippocampus. This remains the most-cited mechanism paper in the field.
• •Kolomin, Shadrina, Slominsky and Limborska (Institute of Molecular Genetics): Transcriptomic studies in rodents following a single Semax dose documented differential expression across hundreds of genes, with the strongest reproducible changes in neurotrophin and synaptic plasticity pathways.
• •Stroke studies (Maslov, 2011; Lebedeva, 2018): Semax administered in 2 courses of 6,000 mcg/day for 10 days with a 20-day interval measurably increased plasma BDNF levels in stroke patients. This represents one of the few controlled human data points on Semax's neurotrophic activity.

Important caveat: Semax has a plasma half-life of approximately 2-3 minutes due to rapid peptidase cleavage. Despite this, downstream BDNF/NGF upregulation persists for 24+ hours after a single dose -- the downstream gene expression cascade outlasts the peptide itself. This pharmacokinetic/pharmacodynamic dissociation is well-established and should inform dosing frequency decisions in any research design.

---

Why Intranasal? The Delivery Rationale

Oral administration of Semax is not viable. Gastric and small-intestinal peptidases destroy the peptide on contact; oral bioavailability is effectively zero. Intranasal delivery is the route used in both the Russian clinical literature and the majority of modern Semax research because it:

1. Bypasses first-pass destruction -- nasal mucosa lacks the aggressive protease environment of the GI tract

2. Provides partial direct nose-to-brain transport -- via olfactory and trigeminal neural pathways, avoiding the need for full systemic absorption

3. Achieves CNS uptake rapidly -- research estimates 60-70% absorption through the nasal mucosa, with CNS effects observed within minutes of administration

4. Matches the published evidence base -- virtually all controlled Semax research in humans used intranasal delivery

Subcutaneous (SubQ) administration has been explored in some preclinical models but lacks the human evidence base that intranasal delivery has accumulated across three decades.

---

Semax Concentrations: 0.1% vs. 1%

Research Semax is commonly supplied either as a pre-formulated nasal solution at standardized concentrations, or as lyophilized (freeze-dried) powder requiring reconstitution.

0.1% solution (1 mg/mL): This is the standard starting concentration for cognitive enhancement and nootropic research designs. At ~100 mcg per spray pump, it allows fine-grained dose titration. Most introductory research protocols use this concentration.

1% solution (10 mg/mL): Used in higher-dose neuroprotection research, including protocols modeled on Russian acute ischemic stroke studies. At this concentration, even a small spray volume delivers a substantial dose -- researchers should verify their spray pump calibration before use.

---

Reconstitution Protocol (Research Use)

When working with lyophilized Semax powder, proper reconstitution technique directly affects peptide stability and effective concentration.

Materials Required

• •Lyophilized Semax vial
• •Bacteriostatic water (for multi-use research preparations) or sterile water for injection
• •Sterile syringes (1 mL and 5 mL)
• •Sterile nasal spray pump (metered, 0.1 mL/actuation) or dropper
• •Alcohol prep pads

Step-by-Step Reconstitution

1. Equilibrate to room temperature. Remove the lyophilized vial from refrigerated or frozen storage and allow it to warm to room temperature (approximately 15-20 minutes). Injecting cold solvent into a chilled vial can promote aggregation.

2. Determine target concentration. Calculate the solvent volume needed for your target concentration:

- To produce 0.1% (1 mg/mL): Add 1 mL bacteriostatic water per 1 mg of peptide (e.g., 5 mg vial + 5 mL = 1 mg/mL)

- To produce 1% (10 mg/mL): Add 1 mL per 10 mg of peptide (e.g., 10 mg vial + 1 mL = 10 mg/mL)

3. Add solvent slowly. Insert the syringe needle through the stopper at an angle. Inject bacteriostatic water slowly down the inside wall of the vial -- never directly onto the lyophilized cake. Shear forces from direct injection can denature the peptide and reduce effective yield by 20-30%.

4. Swirl gently, do not shake. Rotate the vial gently between your fingers until the powder is fully dissolved. Semax lyophilizate dissolves rapidly; vigorous shaking introduces air bubbles and mechanical stress.

5. Inspect before use. The reconstituted solution should be clear and colorless. Discard if cloudy, particulate, or discolored.

6. Transfer to spray pump or dropper. For nasal spray research, draw the solution into a metered nasal pump (standard pump delivers ~0.1 mL per actuation). Label with concentration, date of reconstitution, and compound identity.

Spray Dose Calculation Examples

For reconstitution volume calculations across peptide compounds, the site's Reconstitution Calculator provides a standardized reference tool.

---

Research Dosage Ranges

The following ranges are drawn from published preclinical studies, Russian clinical protocols, and investigational research logs. These are not clinical recommendations.

Cognitive Research Protocols

Published cognitive and nootropic research designs generally use doses in the 300-1,200 mcg/day range, administered intranasally in divided doses.

Lebedeva et al. (2018) pilot study: 24 healthy subjects received 1% intranasal Semax (total dose: 1.2 mg). Resting fMRI showed increased default mode network signal in the rostral subcomponent versus placebo -- one of the few controlled neuroimaging studies in healthy human subjects.

Attention and memory studies: Doses of 250-1,000 mcg/kg in healthy subjects produced improvements in attention and short-term memory with EEG changes consistent with other neuroprotective compounds.

Timing Recommendations

• •Time of administration: Most research protocols administer Semax in the morning, as BDNF upregulation and the downstream neurotrophic cascade may affect sleep architecture if dosed late in the day.
• •Divided dosing: For higher-dose protocols (e.g., stroke-model research), doses are divided into 3-4 administrations across the day at 3-4 hour intervals to maintain neuromodulatory presence, given the peptide's short plasma half-life.
• •Cycling: Research protocols commonly use 10-14 days on, 7-10 days off for nootropic applications, reflecting the sustained downstream BDNF effect and allowing investigation of washout characteristics.

---

Storage Requirements

Proper storage is essential for peptide integrity. Temperature excursions above 8 degrees C or repeated freeze-thaw cycles can reduce Semax bioavailability by 40-60%.

Protect from light. Semax solutions should be stored in amber vials or kept shielded from UV exposure; light degradation can reduce potency over extended storage periods.

Label all vials with: compound, concentration, reconstitution date, and solvent used.

---

Research Considerations and Limitations

CNS modulation beyond BDNF: Semax has been shown to modulate dopaminergic and serotonergic systems in rodent models, including attenuation of amphetamine-evoked locomotor effects. This is framed as neuromodulation rather than classic agonist/antagonist pharmacology, but researchers designing behavioral studies should account for potential monoaminergic interactions.

BDNF and hair cycle: A small body of literature links BDNF stimulation to hair cycle regulation. Researchers studying Semax in dermatological or systemic BDNF-related models should be aware of this secondary pathway.

Long-term safety data: Most controlled research extends 10-30 days. Long-term safety data in humans is limited; the Russian clinical literature provides the longest observational record but lacks the controlled trial design required for definitive safety characterization.

Comparing Semax to related neuropeptides? Use the peptide comparison tool for structured, side-by-side compound comparisons.

---

Research Study Designs: Key Semax Protocols

Understanding how Semax has been studied helps researchers design appropriate protocols.

Cognitive Enhancement Models

The most common research design in the nootropic literature uses a 10-14 day protocol with intranasal delivery:

• •Dose range: 300-900 mcg/day in 2-3 divided doses
• •Timing: Morning and early afternoon administration (stimulating profile suggests morning front-loading)
• •Outcome measures: Standardized cognitive battery tests, reaction time, working memory (typically rodent Morris Water Maze or human neuropsychological assessment)
• •Rest period: 7-10 days off between cycles to assess sustained vs. transient effects

Neuroprotection and Stroke Models

The most clinically relevant human data comes from Russian stroke research:

• •Maslov et al. (2011): 6,000 mcg/day intranasally for 10 days per course, 2 courses separated by 20 days. Outcome: measurable BDNF elevation and improved stroke rehabilitation metrics.
• •Lebedeva et al. (2018): Same high-dose paradigm. Used brain MRI and plasma BDNF as biomarkers. Demonstrated dose-dependent BDNF response.
• •Preclinical acute models: Single high doses (up to 500 mcg/kg in rodents) 30 minutes post-ischemia onset. Neuroprotective window appears widest within 6 hours of injury.

Anxiolysis vs Stimulation: Separating Variables

A recurring challenge in Semax research design is that the compound produces stimulating CNS effects that must be controlled against confounding anxiogenic responses in high-stress paradigms. Researchers using forced-swim or open-field tests should account for Semax's known locomotor and motivational effects when interpreting behavioral data.

---

Semax Side Effect Profile in Research

Semax has one of the longer observational safety records among research neuropeptides, accumulated across 30+ years of Russian investigational and clinical use.

Commonly Reported Effects in Research Subjects

Effects NOT Observed in the Published Literature

Several theoretically plausible adverse effects have not been reported in controlled Semax research:

• •No adrenocortical activation: Unlike ACTH itself, Semax lacks the cortisol-stimulating sequence; HPA-axis disruption has not been documented
• •No hepatotoxicity or nephrotoxicity in multi-week rodent studies
• •No androgenic effects: Semax does not interact with sex steroid pathways
• •No dependency or withdrawal syndrome: Cessation of Semax research protocols does not produce withdrawal-pattern behaviors in rodent models

Important Caveat

Most controlled safety data extends only 10-30 days. Long-term (>90 day) safety characterization in humans is not established in the peer-reviewed literature. The Russian clinical experience provides the broadest observational record but was conducted under Soviet-era regulatory frameworks that differ from modern controlled trial standards.

---

Semax vs Selank: The Sister Compound Distinction

Semax and Selank are frequently discussed together because they share developmental origins (both emerged from the Institute of Molecular Genetics, Russian Academy of Sciences), similar delivery formats (intranasal 0.1% and 1% solutions), and overlapping research interest in cognitive and neuroprotective applications. However, their pharmacological profiles diverge significantly.

When to consider Selank instead of Semax: Research designs focused on anxiolysis, GABA-adjacent mechanisms, or stress resilience tend to favor Selank's profile. Semax is preferred when the research question centers on neurotrophic factors, cognitive performance under non-stressed conditions, or stroke/ischemia neuroprotection.

For a full side-by-side comparison including research citations, see the Semax vs Selank Research Comparison Guide on this site.

---

Where Researchers Source Semax

Semax sourcing follows the same considerations as other research peptides: purity documentation, supplier transparency, and appropriate labeling for research use.

Key sourcing criteria for research applications:

• •HPLC purity certification: Research-grade Semax should be ≥98% pure by HPLC. Request the certificate of analysis (CoA) before procurement.
• •Mass spectrometry verification: A CoA showing both HPLC purity AND mass spec confirmation of correct molecular weight (MW 887.02 g/mol for the heptapeptide sequence) provides the strongest quality assurance.
• •RUO labeling: Legitimate research suppliers label Semax as "For Research Use Only. Not for Human Consumption." This labeling is both regulatory and ethical practice.
• •Nasal spray formulations vs lyophilized: Pre-formulated nasal sprays (0.1% or 1%) are common and convenient; lyophilized powder allows concentration flexibility during reconstitution. Both forms have research applications.

Our platform lists suppliers carrying Semax in both formulations. Researchers can review supplier profiles, purity documentation, and pricing on the Semax supplier listing page, which currently features over 150 verified research suppliers.

---

Summary: Semax Dosage Protocol -- Key Points

• •Mechanism: BDNF/NGF upregulation via ACTH(4-10) analog structure; Pro-Gly-Pro tail adds metabolic stability
• •Route: Intranasal (preferred; best evidence base); SubQ used in some preclinical designs
• •Concentrations: 0.1% (1 mg/mL) for cognitive protocols; 1% (10 mg/mL) for higher-dose neuroprotection research
• •Cognitive dosing range: 300-1,200 mcg/day intranasally in divided doses
• •Neuroprotection range: 2,000-6,000 mcg/day, 3-4x daily, for 10-day courses
• •Cycle: 10-14 days on / 7-10 days off for sustained research programs
• •Storage: Freeze powder at -20 degrees C long-term; reconstituted solution refrigerated up to 30 days
• •Reconstitution: Bacteriostatic water, slow wall injection, gentle swirl, no shake

---

> Research Use Only (RUO): This article is for research and educational purposes only. Semax has not been approved by the FDA for human use in the United States. Researchers should work under appropriate institutional oversight and comply with all applicable regulations governing investigational peptides in their jurisdiction. This content does not constitute medical advice.

---

Sources: Dolotov OV et al., Neurochemical Research, 2006; Lebedeva IV et al., Human Brain Mapping, 2018; Maslov NV et al., cerebrovascular stroke studies, 2011; Kolomin TA et al., Journal of Molecular Neuroscience, 2013; Institute of Molecular Genetics RAS publications, 1985-2024.